Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

Andrew Hyland, PhD, of Roswell Park Comprehensive Cancer Center, received the 2026 John Slade Award from the Society for Research on Nicotine and Tobacco.

Roswell Park Comprehensive Cancer Center's Adult Multidisciplinary Neurofibromatosis Clinic was added to the NF Clinic Network.

Roswell Park Comprehensive Cancer Center highlighted key presentations from its researchers at TCT 2026.

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Monitoring thymidine kinase activity levels may provide insights on response to CDK4/6 inhibitor therapy in breast cancer.

A research team at Roswell Park has identified an immune-suppressing metabolic checkpoint in the tumor microenvironment, and a way to overcome it.

The AACN's Beacon Award for Excellence has been awarded to Roswell Park Comprehensive Cancer Center's Intensive Care Unit.

Roswell Park Comprehensive Cancer Center welcomes Brian Higgins to its board of directors.

IL-36 gamma ‘armored’ CAR T cells boost effectiveness of therapies and help eradicate solid tumors according to researchers at Roswell Park.

A study led by Roswell Park Comprehensive Cancer Center reveals that a patient’s race and ethnicity can affect clinical outcomes for stem cell transplant.

Researchers at Roswell Park Comprehensive Care Center discover method of reducing acute graft-versus-host disease risk in blood cancers.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Roswell Park Comprehensive Cancer Center is pleased to announce the recent accreditation of its rectal cancer program by the National Accreditation Program for Rectal Cancer.

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.

A study led by Roswell Park researchers zeroes in on why some newly diagnosed glioblastoma patients survive longer than others after standard treatment plus SurVaxM.

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Roswell Park Comprehensive Cancer Center endorsed a statement urging health care systems and professionals to choose HPV vaccination for cancer prevention.

Five new faculty members join network; three at St. Joseph’s Health in Syracuse as it launches new services.

Patients with lung cancer who take GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t.

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

Findings suggest that treatment with an FGFR4 inhibitor can disrupt tumor spread in pancreatic cancer.

Health services company recognizes joint care offered through collaboration with Roswell Park Oishei Children’s Hospital.

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

Doctors join cancer center with expertise in surgical and medical oncology, pathology, dermatology, anesthesia.